RESUMEN

This report describes a patient with metastatic malignant melanoma treated with recombinant human interleukin 4 who developed vitiligo and severe Graves' Disease after therapy. The patient has experienced complete remission of melanoma for 49+ months. The association of antitumor response, vitiligo and thyroid disorders is reviewed.

Asunto(s)

Enfermedad de Graves/inducido químicamente , Interleucina-4/efectos adversos , Vitíligo/inducido químicamente , Adulto , Femenino , Humanos , Interleucina-4/uso terapéutico , Melanoma/tratamiento farmacológico , Proteínas Recombinantes , Neoplasias Cutáneas/tratamiento farmacológico